Pfizer has a long and proud history of manufacturing vaccines. In 2019 alone, our vaccines helped to protect more than 69 million people from potentially life-threatening diseases.
We are taking a number of steps to scale up manufacturing operations at risk to accelerate our ability to supply a potential novel vaccine for COVID-19, subject to the vaccine demonstrating effectiveness and gaining approval. We have been planning and developing a strategy to ensure we are able to manufacture large quantities of a vaccine as quickly and safely as possible for patients.
Learn more about our manufacturing and global supply capabilities: